- Certolizumab pegol in the treatment of focal psoriasis2020 | Second Faculty of Medicine
- Tuberculosis and latent tuberculosis in patients with inflammatory bowel disease treated with biologic agents2017 | Faculty of Physical Education and Sport, First Faculty of Medicine
- Advances in treatment of juvenile idiopathic arthritis associated uveitis2021 | Publication without faculty affiliation
- Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Science
- Overview of biological treatment of inflammatory bowel diseases with a focus on TNF-α inhibitors2020 | First Faculty of Medicine
- Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?2014 | Faculty of Medicine in Pilsen
- Pharmacology of golimumab and its use in treating patients with rheumatoid arthritis2013 | Publication without faculty affiliation
- Selected case reports from the tofacitinib clinical program2019 | First Faculty of Medicine
- Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 20132016 | Faculty of Medicine in Pilsen
- TNF-α inhibitors in inflammatory bowel disease therapy2021 | First Faculty of Medicine
- Vedolizumab2017 | First Faculty of Medicine
- Prevalence of genital and oral human papillomavirus infection among psoriasis patients on biologic therapy2022 | Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Science
- Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab2022 | Third Faculty of Medicine
- Vliv adalimumabu na biomarkery kardiovaskulárního rizika u pacientů s psoriázou2017 | Third Faculty of Medicine